Clinical Trials Logo

Stomach Ulcer clinical trials

View clinical trials related to Stomach Ulcer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06002906 Recruiting - Obesity, Morbid Clinical Trials

The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.

Start date: January 25, 2023
Phase: Phase 4
Study type: Interventional

This is an interventional pilot study aimed to evaluate the use of NIF imaging as an intraoperative aid to assess the anastomotic blood flow to the gastric pouch and gastrojejunostomy during Roux-en-Y gastric bypass surgery and to determine its long-term impact on the rate of marginal ulceration, leaks and stricture.

NCT ID: NCT05517408 Recruiting - Gastric Cancer Clinical Trials

Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.

Start date: September 19, 2022
Phase: N/A
Study type: Interventional

Ciprofol is a new anesthetic, which combines with γ- Aminobutyric acid-a (GABAA) receptor. Ciprofol has shown equivalent anesthetic efficacy of propofol at 1/4 to 1/5 of the dosage. Ciprofol has the pharmacodynamic characteristics of rapid onset, stable and rapid recovery. Phase III clinical results showed that the incidence of injection pain and respiratory and circulatory depression of ciprofol was lower than that of propofol. Therefore, ciprofol has a good application prospect in sedation for gastrointestinal endoscopy, especially for obese patients. In the current study, we would explore the proper dose of Ciprofol in sedated gastrointestinal endoscopy in obese patients.

NCT ID: NCT05320796 Recruiting - Obesity Clinical Trials

The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass

Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.

NCT ID: NCT04845438 Recruiting - Bile Reflux Clinical Trials

Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index

Start date: December 29, 2020
Phase: N/A
Study type: Interventional

MGB is considered to be the best alternative to Roux-en-Y gastric bypass (RYGB) due to the shorter operation time and fewer possible complications. The purpose of this study was to determine biliary reflux in patients undergoing MGB/OAGB with a hand-sewn gastroenteroanastomosis, and MGB/OAGB with a stapler gastroenteroanastomosis.

NCT ID: NCT04422405 Recruiting - Obesity, Morbid Clinical Trials

Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB

BiFLux
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Evaluation of the functional changes in the stomach and esophagus of patients undergoing One Anastomosis Gastric Bypass (OAGB)

NCT ID: NCT03972956 Recruiting - Colorectal Cancer Clinical Trials

Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease

Start date: December 23, 2020
Phase:
Study type: Observational

The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and/or normal gastrointestinal tissue (if available) from patients with non-malignant disease (including, but not limited to, inflammatory bowel disease (IBD), gastric ulcer, hemorrhoids or hernia), and to create a database for the collected samples and allow access to relevant clinical information for current and future protocols.

NCT ID: NCT03057171 Recruiting - Clinical trials for Helicobacter Pylori Infection

A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

Start date: May 2015
Phase:
Study type: Observational

Helicobacter pylori (H.pylori) is a major human pathogenic bacterium in gastric mucosa which is linked to the development of gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. However the regulatory mechanism of H.pylori-induced immune response is not clear. Long non-coding RNA (lncRNA) has recently emerged as key post-transcriptional regulators of gene expression, differentiation. The investigators had a preliminary results which THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) and PACER(p50-associated COX-2 extragenic RNA) played a potential role in H.pylori induced inflammatory cascade. However, there wasn't a previous study about expression of THRIL, PACER in a human tissue. Therefore, the investigators aimed to evaluate the expression of THRIL, PACER in patients with gastrointestinal disease according to H.pylori infection.

NCT ID: NCT02108756 Recruiting - Clinical trials for Bleeding Gastric Ulcer

Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding

Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and Efficacy of L- Pantoprazole sodium to treat upper gastrointestinal ulcer bleeding.

NCT ID: NCT01946633 Recruiting - Gastric Ulcer Clinical Trials

Remote-controlled Capsule Endoscopy: a Feasibility Study

Start date: October 2013
Phase: N/A
Study type: Interventional

The present study is a feasibility study to assess the safety and efficacy of wireless capsule endoscope and compare the data obtained with those obtained by using a conventional esophagogastroduodenoscopy. The product was developed and manufacture in China.(the NaviCam. AKC-1.China)

NCT ID: NCT01922765 Recruiting - Clinical trials for Gastritis, Gastric Ulcer, and Duodenal Ulcer

Concomitant Therapy of H. Pylori

Start date: August 2013
Phase: Phase 4
Study type: Interventional

If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin, rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days(sequential), amoxicillin, clarithromycin, metronidazole, rabeprazole(concomitant), then the eradication rate of concomitant group will be the highest.